Medicare Part D Explained

Medicare Part D Explained Anyone that currently has Medicare Part A or B is eligible for prescription drug coverage under Medicare Part D. Medicare Part D is the prescription drug benefit plan enacted in 2006 as part of the Medicare Prescription Drug, Improvement, and Modernization Act. In order to qualify for Medicare Part D, a person with medicare must be enrolled in a stand-alone Prescription Drug Plan or a Medicare Advantage Plan. These plans are designed and executed by private insurance companies but are overseen by the Medicare program. Unlike Medicare Part A and B, Part D is not standardized. This means that the drugs covered can vary widely between providers and drugs covered by one provider may not be covered by another. Critics of the plan say that this leads to unnecessary confusion and may actually prevent many from obtaining prescription drug coverage that they need. To enroll in Medicare Part D, you must select a plan during the annual election period which is November 15th through December 31st. This is also the only time that Medicare recipients can change from one plan to another. If medicare D participants are already enrolled in a plan and wish to remain in the same plan it is not necessary to enroll again. They will simply remain in the same plan the following year. Related Posts Medicare Part D Explained Headache Treatments Covered by Medicare If you suffer from severe migraine headaches and are currently enrolled to receive Medicare benefits, then you may be eligible to receive coverage that will … Will Medicaid Cover Treatments for Severe Headaches? Medicaid is an entitlement program that was created to provide medical assistance to individuals or families with low income. Unlike Medicare, which is funded entirely … Paying for Prescription Migraine Drugs Many chronic migraine headache sufferers find that the only way to relieve their pain is through the use of prescription drugs. Many of these drugs, … share: Recommend on Facebook Share with Stumblers Tweet about it Subscribe to the comments on this post